Pharwar Pharmaceuticals, Inc. is a start-up company that owns the patents of these small molecule chemicals (anti-SIAH1 inhibitors) that could achieve effective neural regeneration, attenuate cocaine addictive behaviors, etc.
US provisional: 63/358,954 (filed on July, 2022)
PCT patent: CN2023/088337 (filed in Apr. 2023; opinions in Aug. 2023). The PCT patent has been deemed to have novelty, inventive step, and industrial applicability.
The research discovery has been submitted to a Prominent Journal.
